Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125386211 | 12538621 | 1 | I | 20160604 | 20160706 | 20160708 | 20160708 | EXP | IT-009507513-1607ITA002336 | MERCK | 59.00 | YR | F | Y | 0.00000 | 20160708 | OT | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125386211 | 12538621 | 1 | PS | LOSARTAN POTASSIUM. | LOSARTAN POTASSIUM | 1 | Oral | 1 DOSE (UNIT), DAILY | U | U | 20386 | 1 | DF | TABLET | QD | ||||
| 125386211 | 12538621 | 2 | SS | APONIL (LACIDIPINE) | LACIDIPINE | 1 | Oral | 4 MG, DAILY | U | 0 | 4 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125386211 | 12538621 | 1 | Hypertension |
| 125386211 | 12538621 | 2 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125386211 | 12538621 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125386211 | 12538621 | Headache | |
| 125386211 | 12538621 | Hypertensive crisis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125386211 | 12538621 | 1 | 201506 | 0 | ||
| 125386211 | 12538621 | 2 | 201506 | 0 |